跳至主要内容
临床试验/JPRN-UMIN000029659
JPRN-UMIN000029659已完成未知

First-in-man study of virtual reality technology-based dual task exercise rehabilitation system (mediVR01) - mediVR01 Study-1

The Japan Society of Clinical Research Department of Clinical Investigation0 个研究点目标入组 30 人开始时间: 2017年10月23日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 100years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Present medical history of dizziness and vertigo 2. Poor visual acuity despite correction 3. Present medical history of epilepsy 4. Sever hypotension 5. Study population of other clinical studies within 3 months 6. Patients with psychiatric disorder 7. Inappropriate candidates (attending physician's discretion)

研究者

发起方
The Japan Society of Clinical Research Department of Clinical Investigation

相似试验

已完成
不适用
First in Human Experience of the St. Jude Medical TAVI Valve and Delivery SystemSymptomatic Aortic Stenosis
NCT01487330Abbott Medical Devices10
进行中(未招募)
1 期
Dose Escalation of DF1001 in Patients With Advanced Solid Tumors, and Expansion in Selected Indicationsocally Advanced or Metastatic Solid Tumors, and Expansion in Selected IndicationsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLGTClassification code 10027476Term: MetastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2019-004706-10-BEDragonfly Therapeutics, Inc.358
招募中
2 期
Dose Escalation of DF1001 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications
2023-503291-24-00Dragonfly Therapeutics Inc.174
招募中
不适用
A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
NL-OMON52911Dragonfly Therapeutics, Inc.25
已完成
1 期
Blood stage pilot challenge study to assess the safety and the infectivity of Plasmodium malariae isolate (HMPBS-Pm) in healthy volunteersMalaria infection with P. malariae strain
ACTRN12617000048381QIMR Berghofer Medical Research Institute2